Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (431-440 of 483) with videos related to

Pageof 49
Sort By:
Blood|February 4, 2021
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphomaFranck Morschhauser, Pierre Feugier, Ian W Flinn, et al.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Liver Cancer|August 11, 2022
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter StudySabrina Welland, Catherine Leyh, Fabian Finkelmeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
International Journal of Molecular Sciences|February 18, 2017
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupLisa Pleyer, Hartmut Döhner, Hervé Dombret, et al.
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
NEJM Evidence|February 6, 2024
Long-Term Outcomes of Adjuvant Denosumab in Breast CancerMichael Gnant, Sophie Frantal, Georg Pfeiler, et al.
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
The Lancet. Haematology|June 12, 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trialUmberto Vitolo, Juan Miguel Bergua Burgues, Johannes Duell, et al.
Blood|September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study GroupFrank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
Pageof 49

Showing results (431-440 of 483) with videos related to

Sort By:
Pageof 49
Blood|February 4, 2021
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphomaFranck Morschhauser, Pierre Feugier, Ian W Flinn, et al.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Liver Cancer|August 11, 2022
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter StudySabrina Welland, Catherine Leyh, Fabian Finkelmeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
International Journal of Molecular Sciences|February 18, 2017
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupLisa Pleyer, Hartmut Döhner, Hervé Dombret, et al.
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
NEJM Evidence|February 6, 2024
Long-Term Outcomes of Adjuvant Denosumab in Breast CancerMichael Gnant, Sophie Frantal, Georg Pfeiler, et al.
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
The Lancet. Haematology|June 12, 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trialUmberto Vitolo, Juan Miguel Bergua Burgues, Johannes Duell, et al.
Blood|September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study GroupFrank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
Pageof 49